| Year |
Citation |
Score |
| 2020 |
Uludağ H, Parent K, Aliabadi HM, Haddadi A. Prospects for RNAi Therapy of COVID-19. Frontiers in Bioengineering and Biotechnology. 8: 916. PMID 32850752 DOI: 10.3389/Fbioe.2020.00916 |
0.309 |
|
| 2020 |
Plianwong S, Thapa B, Kc RB, Kucharski C, Rojanarata T, Uludağ H. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines. Pharmaceutical Research. 37: 46. PMID 32016611 DOI: 10.1007/S11095-020-2770-9 |
0.347 |
|
| 2020 |
Pankongadisak P, Tsekoura E, Suwantong O, Uludağ H. Electrospun gelatin matrices with bioactive pDNA polyplexes. International Journal of Biological Macromolecules. 149: 296-308. PMID 31991211 DOI: 10.1016/J.Ijbiomac.2020.01.252 |
0.368 |
|
| 2019 |
Aliabadi HM, Bahadur K C R, Bousoik E, Hall R, Barbarino A, Thapa B, Coyle M, Mahdipoor P, Uludağ H. A Systematic Comparison of Lipopolymers for siRNA Delivery to Multiple Breast Cancer Cell Lines: In vitro Studies. Acta Biomaterialia. PMID 31760224 DOI: 10.1016/J.Actbio.2019.11.036 |
0.322 |
|
| 2019 |
Remant KC, Thapa B, Valencia-Serna J, Domun SS, Dimitroff C, Jiang X, Uludağ H. Cholesterol Grafted Cationic Lipopolymers: Potential siRNA Carriers for Selective Chronic Myeloid Leukemia (CML) Therapy. Journal of Biomedical Materials Research. Part A. PMID 31714657 DOI: 10.1002/Jbm.A.36837 |
0.376 |
|
| 2019 |
Thapa B, Kc R, Hitt M, Lavasanifar A, Kutsch O, Seol DW, Uludag H. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-delivery of pTRAIL and Complementary siRNAs using Lipopolymers. Human Gene Therapy. PMID 31547718 DOI: 10.1089/Hum.2019.096 |
0.334 |
|
| 2019 |
Valencia-Serna J, Kucharski C, Chen M, Remant KC, Jiang X, Brandwein J, Uludağ H. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using Lipopolymers. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31430499 DOI: 10.1016/J.Jconrel.2019.08.018 |
0.349 |
|
| 2019 |
Uludag H, Ubeda A, Ansari A. At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids. Frontiers in Bioengineering and Biotechnology. 7: 131. PMID 31214586 DOI: 10.3389/Fbioe.2019.00131 |
0.312 |
|
| 2019 |
Thapa B, Remant KC, Uludağ H. siRNA Library Screening to Identify Complementary Therapeutic Pairs in Triple-Negative Breast Cancer Cells. Methods in Molecular Biology (Clifton, N.J.). 1974: 1-19. PMID 31098991 DOI: 10.1007/978-1-4939-9220-1_1 |
0.308 |
|
| 2018 |
Wubneh A, Tsekoura E, Ayranci C, Uludağ H. Current State of Fabrication Technologies and Materials for Bone Tissue Engineering. Acta Biomaterialia. PMID 30248515 DOI: 10.1016/J.Actbio.2018.09.031 |
0.44 |
|
| 2018 |
Parmar MB, K C RB, Löbenberg R, Uludag H. Additive polyplexes to undertake siRNA therapy against CDC20 and survivin in breast cancer cells. Biomacromolecules. PMID 30222931 DOI: 10.1021/Acs.Biomac.8B00918 |
0.364 |
|
| 2018 |
Meneksedag-Erol D, Kizhakkedathu JN, Tang T, Uludag H. Molecular Dynamics Simulations on Nucleic Acid Binding Polymers Designed to Arrest Thrombosis. Acs Applied Materials & Interfaces. PMID 30085650 DOI: 10.1021/Acsami.8B09914 |
0.324 |
|
| 2018 |
Kaur H, Siraki AG, Sharma M, Uludağ H, Dederich DN, Flood P, El-Bialy T. Reactive Oxygen Species Mediate Therapeutic Ultrasound-Induced, Mitogen-Activated Protein Kinase Activation in C28/I2 Chondrocytes. Ultrasound in Medicine & Biology. PMID 30037475 DOI: 10.1016/J.Ultrasmedbio.2018.05.025 |
0.331 |
|
| 2018 |
Valencia-Serna J, Aliabadi HM, Manfrin A, Mohseni M, Jiang X, Uludag H. siRNA/Lipopolymer Nanoparticles to Arrest Growth of Chronic Myeloid Leukemia Cells In Vitro and In Vivo. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. PMID 29913272 DOI: 10.1016/J.Ejpb.2018.06.018 |
0.373 |
|
| 2018 |
Sezlev Bilecen D, Uludag H, Hasirci V. Development of PEI-RANK siRNA Complex Loaded PLGA Nanocapsules for the Treatment of Osteoporosis. Tissue Engineering. Part A. PMID 29652606 DOI: 10.1089/Ten.Tea.2017.0476 |
0.469 |
|
| 2018 |
Parmar MB, Meenakshi Sundaram DN, K C RB, Maranchuk R, Montazeri Aliabadi H, Hugh JC, Löbenberg R, Uludağ H. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Acta Biomaterialia. 66: 294-309. PMID 29183848 DOI: 10.1016/J.Actbio.2017.11.036 |
0.332 |
|
| 2017 |
Tsekoura EK, K C RB, Uludag H. Biomaterials to Facilitate Delivery of RNA Agents in Bone Regeneration and Repair. Acs Biomaterials Science & Engineering. 3: 1195-1206. PMID 33440509 DOI: 10.1021/acsbiomaterials.6b00387 |
0.3 |
|
| 2017 |
Ansari AS, Santerre PJ, Uludağ H. Biomaterials for polynucleotide delivery to anchorage-independent cells. Journal of Materials Chemistry. B. 5: 7238-7261. PMID 32264174 DOI: 10.1039/C7Tb01833A |
0.335 |
|
| 2017 |
Meneksedag-Erol D, Tang T, Uludağ H. Mechanistic insights into the role of glycosaminoglycans in delivery of polymeric nucleic acid nanoparticles by molecular dynamics simulations. Biomaterials. 156: 107-120. PMID 29195180 DOI: 10.1016/J.Biomaterials.2017.11.037 |
0.325 |
|
| 2017 |
Thapa B, Bahadur Kc R, Uludağ H. Novel Targets for Sensitizing Breast Cancer Cells to TRAIL-Induced Apoptosis with siRNA Delivery. International Journal of Cancer. PMID 28960310 DOI: 10.1002/Ijc.31079 |
0.33 |
|
| 2017 |
Sezlev Bilecen D, Rodriguez-Cabello JC, Uludag H, Hasirci V. Construction of a PLGA Based, Targeted siRNA Delivery System for Treatment of Osteoporosis. Journal of Biomaterials Science. Polymer Edition. 1-31. PMID 28722515 DOI: 10.1080/09205063.2017.1354675 |
0.473 |
|
| 2017 |
Remant Bahadur KC, Thapa B, Valencia-Serna J, Aliabadi HM, Uludağ H. Nucleic acid combinations: A new frontier for cancer treatment. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 28450205 DOI: 10.1016/J.Jconrel.2017.04.029 |
0.309 |
|
| 2017 |
Meenakshi Sundaram DN, Kucharski C, Parmar MB, Kc RB, Uludağ H. Polymeric Delivery of siRNA against Integrin-β1 (CD29) to Reduce Attachment and Migration of Breast Cancer Cells. Macromolecular Bioscience. PMID 28160423 DOI: 10.1002/Mabi.201600430 |
0.324 |
|
| 2017 |
Pezzoli D, Tsekoura EK, Remant Bahadur K, Candiani G, Mantovani D, Uludağ H. Hydrophobe-substituted bPEI derivatives: boosting transfection on primary vascular cells Science China Materials. 60: 529-542. DOI: 10.1007/S40843-017-9030-7 |
0.347 |
|
| 2016 |
Kaur H, Uludağ H, Dederich DN, El-Bialy T. Effect of Increasing Low-Intensity Pulsed Ultrasound and a Functional Appliance on the Mandibular Condyle in Growing Rats. Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine. PMID 27925675 DOI: 10.7863/Ultra.15.06063 |
0.309 |
|
| 2016 |
Aliabadi HM, Mahdipoor P, Bisoffi M, Hugh JC, Uludag H. Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and non-Targeted Mediators after siRNA Treatment. Molecular Pharmaceutics. PMID 27802596 DOI: 10.1021/Acs.Molpharmaceut.6B00711 |
0.32 |
|
| 2016 |
Parmar MB, Arteaga Ballesteros BE, Fu T, Bahadur Kc R, Aliabadi HM, Hugh JC, Löbenberg R, Uludağ H. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and non-malignant cells. Journal of Biomedical Materials Research. Part A. PMID 27465922 DOI: 10.1002/Jbm.A.35846 |
0.385 |
|
| 2016 |
Uludağ H, Landry B, Valencia-Serna J, Remant-Bahadur KC, Meneksedağ-Erol D. Current attempts to implement siRNA-based RNAi in leukemia models. Drug Discovery Today. PMID 27126778 DOI: 10.1016/J.Drudis.2016.04.018 |
0.324 |
|
| 2016 |
Thapa B, Plianwong S, Remant Bahadur KC, Rutherford B, Uludağ H. Small hydrophobe substitution on polyethylenimine for plasmid DNA delivery: Optimal substitution is critical for effective delivery. Acta Biomaterialia. PMID 26802444 DOI: 10.1016/J.Actbio.2016.01.025 |
0.393 |
|
| 2016 |
Landry B, Gül-Uludağ H, Plianwong S, Kucharski C, Zak Z, Parmar MB, Kutsch O, Jiang H, Brandwein J, Uludağ H. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. Journal of Controlled Release : Official Journal of the Controlled Release Society. 224: 8-21. PMID 26742943 DOI: 10.1016/J.Jconrel.2015.12.052 |
0.438 |
|
| 2016 |
Tsekoura EK, K.C. RB, Uludag H. Biomaterials to Facilitate Delivery of RNA Agents in Bone Regeneration and Repair Acs Biomaterials Science & Engineering. 3: 1195-1206. DOI: 10.1021/Acsbiomaterials.6B00387 |
0.425 |
|
| 2015 |
Meneksedag-Erol D, Kc RB, Tang T, Uludağ H. A Delicate Balance When Substituting a Small Hydrophobe onto Low Molecular Weight Polyethylenimine to Improve Its Nucleic Acid Delivery Efficiency. Acs Applied Materials & Interfaces. 7: 24822-32. PMID 26493098 DOI: 10.1021/Acsami.5B07929 |
0.321 |
|
| 2015 |
Landry B, Valencia-Serna J, Gul-Uludag H, Jiang X, Janowska-Wieczorek A, Brandwein J, Uludag H. Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia. Molecular Therapy. Nucleic Acids. 4: e240. PMID 25965550 DOI: 10.1038/Mtna.2015.13 |
0.312 |
|
| 2015 |
Parmar MB, Aliabadi HM, Mahdipoor P, Kucharski C, Maranchuk R, Hugh JC, Uludağ H. Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines. Frontiers in Bioengineering and Biotechnology. 3: 14. PMID 25763370 DOI: 10.3389/Fbioe.2015.00014 |
0.368 |
|
| 2015 |
Aliabadi HM, Mahdipoor P, Uludag H. Abstract B45: A search for ideal siRNA targets involved in pathway cross-talks for combinational silencing in human cancer cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-B45 |
0.336 |
|
| 2015 |
Aliabadi HM, Mahdipoor P, Kucharsky C, Chan N, Uludag H. Abstract A57: Effects of pre-exposure to siRNA on silencing response: Do cells become resistant to siRNA silencing? Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-A57 |
0.304 |
|
| 2015 |
Aliabadi HM, Mahdipoor P, Uludag H. Abstract B15: In vivo analysis of repeated siRNA silencing on protein expression levels Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Tumang15-B15 |
0.35 |
|
| 2015 |
Valencia-Serna J, Remant K, Yang X, Aliabadi HM, Parmar MB, Jiang X, Uludag H. 156. Cationic Lipopolymers for BCR-ABL siRNA Delivery and Growth Arrest in Chronic Myeloid Leukemia Tumors Molecular Therapy. 23: S62-S63. DOI: 10.1016/S1525-0016(16)33761-3 |
0.418 |
|
| 2014 |
Rose L, Mahdipoor P, Kucharski C, Uludağ H. Pharmacokinetics and transgene expression of implanted polyethylenimine-based pDNA complexes. Biomaterials Science. 2: 833-42. PMID 26827752 DOI: 10.1039/C3Bm60200A |
0.333 |
|
| 2014 |
Gul-Uludağ H, Valencia-Serna J, Kucharski C, Marquez-Curtis LA, Jiang X, Larratt L, Janowska-Wieczorek A, Uludağ H. Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells. Leukemia Research. 38: 1299-308. PMID 25262448 DOI: 10.1016/J.Leukres.2014.08.008 |
0.314 |
|
| 2014 |
Kaur H, Uludağ H, El-Bialy T. Effect of nonviral plasmid delivered basic fibroblast growth factor and low intensity pulsed ultrasound on mandibular condylar growth: a preliminary study. Biomed Research International. 2014: 426710. PMID 24967367 DOI: 10.1155/2014/426710 |
0.374 |
|
| 2014 |
Meneksedag-Erol D, Tang T, Uludağ H. Molecular modeling of polynucleotide complexes. Biomaterials. 35: 7068-76. PMID 24856107 DOI: 10.1016/J.Biomaterials.2014.04.103 |
0.346 |
|
| 2013 |
Aliabadi HM, Maranchuk R, Kucharski C, Mahdipoor P, Hugh J, Uludağ H. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy. Journal of Controlled Release : Official Journal of the Controlled Release Society. 172: 219-28. PMID 23994345 DOI: 10.1016/J.Jconrel.2013.08.012 |
0.319 |
|
| 2013 |
Dube B, Rose L, Sawant K, Uludag H. Cholic acid modified 2 kDa polyethylenimine as efficient transfection agent. Biotechnology Progress. 29: 1337-41. PMID 23955845 DOI: 10.1002/Btpr.1799 |
0.385 |
|
| 2013 |
Valencia-Serna J, Gul-Uludağ H, Mahdipoor P, Jiang X, Uludağ H. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 172: 495-503. PMID 23726887 DOI: 10.1016/J.Jconrel.2013.05.014 |
0.392 |
|
| 2013 |
Rose L, Uludağ H. Realizing the potential of gene-based molecular therapies in bone repair. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 2245-62. PMID 23553878 DOI: 10.1002/Jbmr.1944 |
0.486 |
|
| 2013 |
Rose L, Aliabadi HM, Uludağ H. Gelatin coating to stabilize the transfection ability of nucleic acid polyplexes. Acta Biomaterialia. 9: 7429-38. PMID 23542234 DOI: 10.1016/J.Actbio.2013.03.029 |
0.311 |
|
| 2013 |
Aliabadi HM, Mahdipoor P, Uludağ H. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells. Cancer Gene Therapy. 20: 169-77. PMID 23449477 DOI: 10.1038/Cgt.2013.8 |
0.334 |
|
| 2013 |
Wang Y, Mostafa NZ, Hsu CY, Rose L, Kucharki C, Yan J, Jiang H, Uludağ H. Modification of human BMSC with nanoparticles of polymeric biomaterials and plasmid DNA for BMP-2 secretion. The Journal of Surgical Research. 183: 8-17. PMID 23290528 DOI: 10.1016/J.Jss.2012.11.061 |
0.595 |
|
| 2013 |
Rose LC, Fitzsimmons R, Lee P, Krawetz R, Rancourt DE, Uludağ H. Effect of basic fibroblast growth factor in mouse embryonic stem cell culture and osteogenic differentiation. Journal of Tissue Engineering and Regenerative Medicine. 7: 371-82. PMID 22674886 DOI: 10.1002/Term.532 |
0.329 |
|
| 2012 |
Landry B, Aliabadi HM, Samuel A, Gül-Uludağ H, Jiang X, Kutsch O, Uludağ H. Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines. Plos One. 7: e44197. PMID 22952927 DOI: 10.1371/Journal.Pone.0044197 |
0.409 |
|
| 2012 |
Yogasundaram H, Bahniuk MS, Singh HD, Aliabadi HM, Uludağ H, Unsworth LD. BSA Nanoparticles for siRNA Delivery: Coating Effects on Nanoparticle Properties, Plasma Protein Adsorption, and In Vitro siRNA Delivery. International Journal of Biomaterials. 2012: 584060. PMID 22919392 DOI: 10.1155/2012/584060 |
0.338 |
|
| 2012 |
Hsu CY, Uludağ H. Cellular uptake pathways of lipid-modified cationic polymers in gene delivery to primary cells. Biomaterials. 33: 7834-48. PMID 22874502 DOI: 10.1016/J.Biomaterials.2012.06.093 |
0.557 |
|
| 2012 |
Fitzsimmons RE, Uludağ H. Specific effects of PEGylation on gene delivery efficacy of polyethylenimine: interplay between PEG substitution and N/P ratio. Acta Biomaterialia. 8: 3941-55. PMID 22820308 DOI: 10.1016/J.Actbio.2012.07.015 |
0.358 |
|
| 2012 |
Chen C, Uludağ H, Wang Z, Jiang H. Noggin suppression decreases BMP-2-induced osteogenesis of human bone marrow-derived mesenchymal stem cells in vitro. Journal of Cellular Biochemistry. 113: 3672-80. PMID 22740073 DOI: 10.1002/Jcb.24240 |
0.43 |
|
| 2012 |
Hsu CY, Uludağ H. A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine. Nature Protocols. 7: 935-45. PMID 22517260 DOI: 10.1038/Nprot.2012.038 |
0.567 |
|
| 2012 |
Aliabadi HM, Landry B, Mahdipoor P, Hsu CY, Uludağ H. Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 81: 33-42. PMID 22311298 DOI: 10.1016/J.Ejpb.2012.01.011 |
0.568 |
|
| 2012 |
Hsu CY, Uludağ H. Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression. Journal of Drug Targeting. 20: 301-28. PMID 22303844 DOI: 10.3109/1061186X.2012.655247 |
0.546 |
|
| 2012 |
Rose LC, Kucharski C, Uludağ H. Protein expression following non-viral delivery of plasmid DNA coding for basic FGF and BMP-2 in a rat ectopic model. Biomaterials. 33: 3363-74. PMID 22289263 DOI: 10.1016/J.Biomaterials.2012.01.031 |
0.483 |
|
| 2012 |
Wang G, Mostafa NZ, Incani V, Kucharski C, Uludağ H. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases. Journal of Biomedical Materials Research. Part A. 100: 684-93. PMID 22213565 DOI: 10.1002/Jbm.A.34002 |
0.493 |
|
| 2012 |
Aliabadi HM, Landry B, Sun C, Tang T, Uludağ H. Supramolecular assemblies in functional siRNA delivery: where do we stand? Biomaterials. 33: 2546-69. PMID 22209641 DOI: 10.1016/J.Biomaterials.2011.11.079 |
0.343 |
|
| 2012 |
Chen C, Uludağ H, Wang Z, Rezansoff A, Jiang H. Macrophages inhibit migration, metabolic activity and osteogenic differentiation of human mesenchymal stem cells in vitro. Cells, Tissues, Organs. 195: 473-83. PMID 22156615 DOI: 10.1159/000330686 |
0.343 |
|
| 2012 |
Mostafa NZ, Fitzsimmons R, Major PW, Adesida A, Jomha N, Jiang H, Uludağ H. Osteogenic differentiation of human mesenchymal stem cells cultured with dexamethasone, vitamin D3, basic fibroblast growth factor, and bone morphogenetic protein-2. Connective Tissue Research. 53: 117-31. PMID 21966879 DOI: 10.3109/03008207.2011.611601 |
0.407 |
|
| 2012 |
Aliabadi HM, Uludag H. Abstract B32: Impact of Lipid-Substitution on Assembly and Delivery of siRNA by Cationic Polymers Clinical Cancer Research. 18: B32-B32. DOI: 10.1158/1078-0432.Mechres-B32 |
0.386 |
|
| 2012 |
Aliabadi HM, Uludag H. Abstract A65: Combinational siRNA silencing of MCL-1 and P-gp enhances the apoptotic response in Human Breast Cancer Cells Clinical Cancer Research. 18: A65-A65. DOI: 10.1158/1078-0432.Mechres-A65 |
0.317 |
|
| 2012 |
Falamarzian A, Xiong XB, Uludag H, Lavasanifar A. Polymeric micelles for siRNA delivery Journal of Drug Delivery Science and Technology. 22: 43-54. DOI: 10.1016/S1773-2247(12)50004-3 |
0.36 |
|
| 2011 |
Mostafa NZ, Uludağ H, Varkey M, Dederich DN, Doschak MR, El-Bialy TH. In vitro osteogenic induction of human gingival fibroblasts for bone regeneration. The Open Dentistry Journal. 5: 139-45. PMID 21915227 DOI: 10.2174/1874210601105010139 |
0.462 |
|
| 2011 |
Wang G, Babadağli ME, Uludağ H. Bisphosphonate-derivatized liposomes to control drug release from collagen/hydroxyapatite scaffolds. Molecular Pharmaceutics. 8: 1025-34. PMID 21557579 DOI: 10.1021/Mp200028W |
0.365 |
|
| 2011 |
Zhi L, Chen C, Pang X, Uludag H, Jiang H. Synergistic effect of recombinant human bone morphogenic protein-7 and osteogenic differentiation medium on human bone-marrow-derived mesenchymal stem cells in vitro. International Orthopaedics. 35: 1889-95. PMID 21487672 DOI: 10.1007/S00264-011-1247-1 |
0.467 |
|
| 2011 |
Hsu CY, Hendzel M, Uludaǧ H. Improved transfection efficiency of an aliphatic lipid substituted 2 kDa polyethylenimine is attributed to enhanced nuclear association and uptake in rat bone marrow stromal cell. The Journal of Gene Medicine. 13: 46-59. PMID 21259408 DOI: 10.1002/jgm.1526 |
0.55 |
|
| 2011 |
Bahadur KC, Landry B, Aliabadi HM, Lavasanifar A, Uludağ H. Lipid substitution on low molecular weight (0.6-2.0 kDa) polyethylenimine leads to a higher zeta potential of plasmid DNA and enhances transgene expression. Acta Biomaterialia. 7: 2209-17. PMID 21256988 DOI: 10.1016/J.Actbio.2011.01.027 |
0.359 |
|
| 2011 |
Zhang D, Chu F, Yang Y, Xia L, Zeng D, Uludağ H, Zhang X, Qian Y, Jiang X. Orthodontic tooth movement in alveolar cleft repaired with a tissue engineering bone: an experimental study in dogs. Tissue Engineering. Part A. 17: 1313-25. PMID 21226625 DOI: 10.1089/Ten.Tea.2010.0490 |
0.463 |
|
| 2011 |
Remant Bahadur KC, Uludağ H. A comparative evaluation of disulfide-linked and hydrophobically-modified PEI for plasmid delivery. Journal of Biomaterials Science. Polymer Edition. 22: 873-92. PMID 20573316 DOI: 10.1163/092050610X496297 |
0.379 |
|
| 2010 |
Alshamsan A, Haddadi A, Hamdy S, Samuel J, El-Kadi AO, Uludağ H, Lavasanifar A. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Molecular Pharmaceutics. 7: 1643-54. PMID 20804176 DOI: 10.1021/Mp100067U |
0.321 |
|
| 2010 |
Abbasi M, Lavasanifar A, Berthiaume LG, Weinfeld M, Uludağ H. Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells. Cancer. 116: 5544-54. PMID 20715163 DOI: 10.1002/Cncr.25321 |
0.316 |
|
| 2010 |
Taghavi CE, Lee KB, He W, Keorochana G, Murray SS, Brochmann EJ, Uludag H, Behnam K, Wang JC. Bone morphogenetic protein binding peptide mechanism and enhancement of osteogenic protein-1 induced bone healing. Spine. 35: 2049-56. PMID 20581758 DOI: 10.1097/Brs.0B013E3181Cc0220 |
0.479 |
|
| 2010 |
Xiong XB, Uludağ H, Lavasanifar A. Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials. 31: 5886-93. PMID 20427082 DOI: 10.1016/J.Biomaterials.2010.03.075 |
0.336 |
|
| 2010 |
Bhandari KH, Newa M, Uludag H, Doschak MR. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin. International Journal of Pharmaceutics. 394: 26-34. PMID 20412845 DOI: 10.1016/J.Ijpharm.2010.04.015 |
0.529 |
|
| 2010 |
Wang G, Kucharski C, Lin X, Uludağ H. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration. Journal of Drug Targeting. 18: 611-26. PMID 20158316 DOI: 10.3109/10611861003622560 |
0.401 |
|
| 2010 |
Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludağ H. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials. 31: 1420-8. PMID 19913908 DOI: 10.1016/J.Biomaterials.2009.11.003 |
0.326 |
|
| 2010 |
Wang S, Zhang Z, Xia L, Zhao J, Sun X, Zhang X, Ye D, Uludağ H, Jiang X. Systematic evaluation of a tissue-engineered bone for maxillary sinus augmentation in large animal canine model. Bone. 46: 91-100. PMID 19761881 DOI: 10.1016/J.Bone.2009.09.008 |
0.426 |
|
| 2010 |
Incani V, Lavasanifar A, Uludağ H. Lipid and hydrophobic modification of cationic carriers on route to superior gene vectors Soft Matter. 6: 2124. DOI: 10.1039/B916362J |
0.364 |
|
| 2009 |
Incani V, Lin X, Lavasanifar A, Uludağ H. Relationship between the extent of lipid substitution on poly(L-lysine) and the DNA delivery efficiency. Acs Applied Materials & Interfaces. 1: 841-8. PMID 20356010 DOI: 10.1021/Am8002445 |
0.392 |
|
| 2009 |
Doschak MR, Kucharski CM, Wright JE, Zernicke RF, Uludağ H. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Molecular Pharmaceutics. 6: 634-40. PMID 19718808 DOI: 10.1021/Mp8002368 |
0.428 |
|
| 2009 |
Zhang S, Doschak MR, Uludağ H. Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine-coated albumin nanoparticles. Biomaterials. 30: 5143-55. PMID 19540582 DOI: 10.1016/J.Biomaterials.2009.05.060 |
0.388 |
|
| 2009 |
Clements BA, Hsu CY, Kucharski C, Lin X, Rose L, Uludağ H. Nonviral delivery of basic fibroblast growth factor gene to bone marrow stromal cells. Clinical Orthopaedics and Related Research. 467: 3129-37. PMID 19495899 DOI: 10.1007/S11999-009-0900-0 |
0.668 |
|
| 2009 |
Zhang S, Uludağ H. Nanoparticulate systems for growth factor delivery. Pharmaceutical Research. 26: 1561-80. PMID 19415467 DOI: 10.1007/S11095-009-9897-Z |
0.357 |
|
| 2009 |
Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A, Uludağ H. Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Molecular Pharmaceutics. 6: 121-33. PMID 19053537 DOI: 10.1021/Mp8000815 |
0.363 |
|
| 2008 |
Zhang S, Wang G, Lin X, Chatzinikolaidou M, Jennissen HP, Laub M, Uludağ H. Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery. Biotechnology Progress. 24: 945-56. PMID 19194903 DOI: 10.1002/Btpr.12 |
0.353 |
|
| 2008 |
Wang G, Siggers K, Zhang S, Jiang H, Xu Z, Zernicke RF, Matyas J, Uludağ H. Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharmaceutical Research. 25: 2896-909. PMID 18709447 DOI: 10.1007/S11095-008-9692-2 |
0.376 |
|
| 2008 |
Xiong XB, Mahmud A, Uludağ H, Lavasanifar A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharmaceutical Research. 25: 2555-66. PMID 18636321 DOI: 10.1007/S11095-008-9673-5 |
0.333 |
|
| 2008 |
Abbasi M, Uludag H, Incani V, Hsu CY, Jeffery A. Further investigation of lipid-substituted poly(L-Lysine) polymers for transfection of human skin fibroblasts. Biomacromolecules. 9: 1618-30. PMID 18498191 DOI: 10.1021/bm800132n |
0.5 |
|
| 2008 |
Wang G, Uludag H. Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. Expert Opinion On Drug Delivery. 5: 499-515. PMID 18491978 DOI: 10.1517/17425247.5.5.499 |
0.303 |
|
| 2008 |
Hsu CY, Uludağ H. Effects of size and topology of DNA molecules on intracellular delivery with non-viral gene carriers. Bmc Biotechnology. 8: 23. PMID 18312664 DOI: 10.1186/1472-6750-8-23 |
0.515 |
|
| 2008 |
Zhang S, Wang G, Jennissen H, Chatzinikolaidou M, Uludag H. Bone morphogenetic protein-2 delivery systems based on polyethylenimine- coated albumin nanoparticles 8th World Biomaterials Congress 2008. 3: 1624. |
0.322 |
|
| 2007 |
Clements BA, Incani V, Kucharski C, Lavasanifar A, Ritchie B, Uludağ H. A comparative evaluation of poly-L-lysine-palmitic acid and Lipofectamine 2000 for plasmid delivery to bone marrow stromal cells. Biomaterials. 28: 4693-704. PMID 17686514 DOI: 10.1016/J.Biomaterials.2007.07.023 |
0.456 |
|
| 2007 |
Zhang S, Wright JE, Ozber N, Uludağ H. The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite. Macromolecular Bioscience. 7: 656-70. PMID 17457941 DOI: 10.1002/Mabi.200600286 |
0.452 |
|
| 2007 |
Varkey M, Kucharski C, Doschak MR, Winn SR, Brochmann EJ, Murray S, Matyas JR, Zernicke RF, Uludag H. Osteogenic response of bone marrow stromal cells from normal and ovariectomized rats treated with a low dose of basic fibroblast growth factor. Tissue Engineering. 13: 809-17. PMID 17394387 DOI: 10.1089/Ten.2006.0348 |
0.451 |
|
| 2007 |
Incani V, Tunis E, Clements BA, Olson C, Kucharski C, Lavasanifar A, Uludag H. Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells. Journal of Biomedical Materials Research. Part A. 81: 493-504. PMID 17340629 DOI: 10.1002/Jbm.A.31249 |
0.469 |
|
| 2007 |
Abbasi M, Uludag H, Incani V, Olson C, Lin X, Clements BA, Rutkowski D, Ghahary A, Weinfeld M. Palmitic acid-modified poly-L-lysine for non-viral delivery of plasmid DNA to skin fibroblasts. Biomacromolecules. 8: 1059-63. PMID 17335285 DOI: 10.1021/Bm060940X |
0.331 |
|
| 2007 |
Zhang S, Gangal G, Uludağ H. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chemical Society Reviews. 36: 507-31. PMID 17325789 DOI: 10.1039/B512310K |
0.489 |
|
| 2007 |
Xiong XB, Mahmud A, Uludağ H, Lavasanifar A. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. Biomacromolecules. 8: 874-84. PMID 17315946 DOI: 10.1021/Bm060967G |
0.327 |
|
| 2007 |
Farrell LL, Pepin J, Kucharski C, Lin X, Xu Z, Uludag H. A comparison of the effectiveness of cationic polymers poly-L-lysine (PLL) and polyethylenimine (PEI) for non-viral delivery of plasmid DNA to bone marrow stromal cells (BMSC). European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 65: 388-97. PMID 17240127 DOI: 10.1016/J.Ejpb.2006.11.026 |
0.439 |
|
| 2006 |
Clements BA, Bai J, Kucharski C, Farrell LL, Lavasanifar A, Ritchie B, Ghahary A, Uludag H. RGD conjugation to polyethyleneimine does not improve DNA delivery to bone marrow stromal cells. Biomacromolecules. 7: 1481-8. PMID 16677029 DOI: 10.1021/Bm060073W |
0.473 |
|
| 2006 |
Wright JE, Gittens SA, Bansal G, Kitov PI, Sindrey D, Kucharski C, Uludağ H. A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages. Biomaterials. 27: 769-84. PMID 16055182 DOI: 10.1016/J.Biomaterials.2005.06.012 |
0.763 |
|
| 2006 |
Uludag H, Incani V, Tunis E, Acan B, Olsen C, Kucharski C, Ghahary A, Lavasanifar A. Potential of lipid-modified polycations to transfer plasmid DNA into bone marrow stromal cells (BMSC) Journal of Biomechanics. 39: S259. DOI: 10.1016/S0021-9290(06)83989-8 |
0.34 |
|
| 2006 |
Hsu CY, Kucharski C, Uludag H. 530. The Effects DNA Molecular Weights and Conformations on Cell Uptake and the Binding Interaction with Cationic Polymers Used for Non-Viral Gene Delivery Molecular Therapy. 13: S203-S204. DOI: 10.1016/J.Ymthe.2006.08.601 |
0.324 |
|
| 2006 |
Clements BA, Incani V, Kucharski C, Lavasanifar A, Uludag H. 200. A Novel Non-Viral Polymer for Plasmid Delivery to Bone Marrow Stromal Cells (BMSC) Molecular Therapy. 13: S78. DOI: 10.1016/J.Ymthe.2006.08.224 |
0.504 |
|
| 2006 |
Jiang X, Bai J, Gittens SA, Uludaǧ H. Growth of bone marrow stromal cells on RGD-grafted thermoreversible (NiPAM) polymers Materialwissenschaft Und Werkstofftechnik. 37: 462-468. DOI: 10.1002/Mawe.200600020 |
0.766 |
|
| 2005 |
Gittens SA, Bansal G, Kucharski C, Borden M, Uludag H. Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes. Molecular Pharmaceutics. 2: 392-406. PMID 16196492 DOI: 10.1021/Mp050017U |
0.786 |
|
| 2005 |
Zhang S, Wright JE, Bansal G, Cho P, Uludag H. Cleavage of disulfide-linked fetuin-bisphosphonate conjugates with three physiological thiols. Biomacromolecules. 6: 2800-8. PMID 16153121 DOI: 10.1021/Bm050273S |
0.511 |
|
| 2005 |
Bansal G, Wright JE, Zhang S, Zernicke RF, Uludag H. Imparting mineral affinity to proteins with thiol-labile disulfide linkages. Journal of Biomedical Materials Research. Part A. 74: 618-28. PMID 16037953 DOI: 10.1002/Jbm.A.30334 |
0.413 |
|
| 2005 |
Smith E, Yang J, McGann L, Sebald W, Uludag H. RGD-grafted thermoreversible polymers to facilitate attachment of BMP-2 responsive C2C12 cells. Biomaterials. 26: 7329-38. PMID 16019067 DOI: 10.1016/J.Biomaterials.2005.05.060 |
0.389 |
|
| 2005 |
Bansal G, Wright JE, Kucharski C, Uludağ H. A dendritic tetra(bisphosphonic acid) for improved targeting of proteins to bone. Angewandte Chemie (International Ed. in English). 44: 3710-4. PMID 15880536 DOI: 10.1002/Anie.200500350 |
0.473 |
|
| 2005 |
Gittens SA, Bansal G, Zernicke RF, Uludağ H. Designing proteins for bone targeting. Advanced Drug Delivery Reviews. 57: 1011-36. PMID 15876401 DOI: 10.1016/J.Addr.2004.12.015 |
0.801 |
|
| 2005 |
Haque T, Uludag H, Zernicke RF, Winn SR, Sebald W. Bone marrow cells from normal and ovariectomized rats respond differently to basic fibroblast growth factor and bone morphogenetic protein 2 treatment in vitro. Tissue Engineering. 11: 634-44. PMID 15869440 DOI: 10.1089/Ten.2005.11.634 |
0.426 |
|
| 2004 |
Varkey M, Gittens SA, Uludag H. Growth factor delivery for bone tissue repair: an update. Expert Opinion On Drug Delivery. 1: 19-36. PMID 16296718 DOI: 10.1517/17425247.1.1.19 |
0.801 |
|
| 2004 |
Wright JE, Zhao L, Choi P, Uludag H. Simulating hydroxyapatite binding of bone-seeking bisphosphonates. Advances in Experimental Medicine and Biology. 553: 139-48. PMID 15503453 DOI: 10.1007/978-0-306-48584-8_11 |
0.487 |
|
| 2004 |
Norrie B, Jalil A, Lakey JR, Rajotte RV, Uludag H. In-situ crosslinking thermoreversible polymers for cell entrapment. Advances in Experimental Medicine and Biology. 553: 19-28. PMID 15503444 DOI: 10.1007/978-0-306-48584-8_2 |
0.327 |
|
| 2004 |
Bansal G, Gittens SA, Uludağ H. A di(bisphosphonic acid) for protein coupling and targeting to bone. Journal of Pharmaceutical Sciences. 93: 2788-99. PMID 15368528 DOI: 10.1002/Jps.20186 |
0.801 |
|
| 2004 |
Gittens SA, Bagnall K, Matyas JR, Löbenberg R, Uludag H. Imparting bone mineral affinity to osteogenic proteins through heparin-bisphosphonate conjugates. Journal of Controlled Release : Official Journal of the Controlled Release Society. 98: 255-68. PMID 15262417 DOI: 10.1016/J.Jconrel.2004.05.001 |
0.775 |
|
| 2004 |
Gittens SA, Wohl GR, Zernicke RF, Matyas JR, Morley P, Uludag H. Systemic bone formation with weekly PTH administration in ovariectomized rats. Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society For Pharmaceutical Sciences, SociéTé Canadienne Des Sciences Pharmaceutiques. 7: 27-37. PMID 15144732 |
0.762 |
|
| 2004 |
Gittens SA, Kitov PI, Matyas JR, Löbenberg R, Uludağ H. Impact of tether length on bone mineral affinity of protein-bisphosphonate conjugates. Pharmaceutical Research. 21: 608-16. PMID 15139517 DOI: 10.1023/B:Pham.0000022407.05163.01 |
0.79 |
|
| 2004 |
Bai J, Açan B, Ghahary A, Ritchie B, Somayaji V, Uludağ H. Poly(ethyleneimine)/arginine-glycine-aspartic acid conjugates prepared withN-succinimidyl 3-(2-pyridyldithio)propionate: An investigation of peptide coupling and conjugate stability Journal of Polymer Science Part a: Polymer Chemistry. 42: 6143-6156. DOI: 10.1002/Pola.20472 |
0.318 |
|
| 2004 |
Jiang X, Bai J, Uludag H, Zhang Z. Effect of RGD-grafted thermoreversible polymers on bone marrow stromal cell growth and alkaline phosphatase activity Transactions - 7th World Biomaterials Congress. 1320. |
0.336 |
|
| 2004 |
Haque T, Uludag H, Zernicke RF, Winn SR. Osteogenic response of bone marrow stromal cells from normal and ovariectomized rats to bFGF and BMP-2 Transactions - 7th World Biomaterials Congress. 901. |
0.32 |
|
| 2004 |
Gittens SA, Matyas JR, Loebenberg R, Zernicke RF, Uludag H. Enhancing glycoprotein affinity to hydroxyapatite bone substitutes in vitro and in vivo Transactions - 7th World Biomaterials Congress. 1539. |
0.789 |
|
| 2003 |
Gittens SA, Matyas JR, Zernicke RF, Uludağ H. Imparting bone affinity to glycoproteins through the conjugation of bisphosphonates. Pharmaceutical Research. 20: 978-87. PMID 12880282 DOI: 10.1023/A:1024445903306 |
0.794 |
|
| 2003 |
Smith E, Bai J, Oxenford C, Yang J, Somayaji R, Uludag H. Conjugation of arginine-glycine-aspartic acid peptides to thermoreversible N-isopropylacrylamide polymers Journal of Polymer Science, Part a: Polymer Chemistry. 41: 3989-4000. DOI: 10.1002/Pola.10965 |
0.315 |
|
| 2002 |
Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Current Pharmaceutical Design. 8: 1929-44. PMID 12171528 DOI: 10.2174/1381612023393585 |
0.474 |
|
| 2002 |
Gao TJ, Kousinioris NA, Wozney JM, Winn S, Uludag H. Synthetic thermoreversible polymers are compatible with osteoinductive activity of recombinant human bone morphogenetic protein 2. Tissue Engineering. 8: 429-40. PMID 12167229 DOI: 10.1089/107632702760184691 |
0.423 |
|
| 2002 |
Uludag H, Yang J. Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnology Progress. 18: 604-11. PMID 12052079 DOI: 10.1021/Bp0200447 |
0.537 |
|
| 2001 |
Gittens SA, Uludag H. Growth factor delivery for bone tissue engineering. Journal of Drug Targeting. 9: 407-29. PMID 11822814 DOI: 10.3109/10611860108998776 |
0.787 |
|
| 2001 |
Gao T, Uludag H. Effect of molecular weight of thermoreversible polymer on in vivo retention of rhBMP-2 Journal of Biomedical Materials Research. 57: 92-100. PMID 11416854 DOI: 10.1002/1097-4636(200110)57:1<92::Aid-Jbm1146>3.0.Co;2-1 |
0.331 |
|
| 2001 |
Uludag H, Norrie B, Kousinioris N, Gao T. Engineering temperature-sensitive poly(N-Isopropylacrylamide) polymers as carriers of therapeutic proteins Biotechnology and Bioengineering. 73: 510-521. PMID 11344456 DOI: 10.1002/Bit.1086 |
0.4 |
|
| 2001 |
Uludag H, Gao T, Porter TJ, Friess W, Wozney JM. Delivery systems for BMPs: Factors contributing to protein retention at an application site Journal of Bone and Joint Surgery - Series A. 83. DOI: 10.2106/00004623-200100002-00007 |
0.499 |
|
| 2001 |
Gao T, Kousinioris N, Winn SR, Wozney JM, Uludag H. Enhanced retention of rhBMP-2 in vivo by thermoreversible polymers Materialwissenschaft Und Werkstofftechnik. 32: 953-961. DOI: 10.1002/1521-4052(200112)32:12<953::Aid-Mawe953>3.0.Co;2-1 |
0.378 |
|
| 2000 |
Uludag H, Gao T, Wohl GR, Kantoci D, Zernicke RF. Bone affinity of a bisphosphonate-conjugated protein in vivo. Biotechnology Progress. 16: 1115-8. PMID 11101342 DOI: 10.1021/Bp000066Y |
0.515 |
|
| 2000 |
Uludag H, Kousinioris N, Gao T, Kantoci D. Bisphosphonate conjugation to proteins as a means to impart bone affinity Biotechnology Progress. 16: 258-267. PMID 10753453 DOI: 10.1021/Bp990154M |
0.533 |
|
| 2000 |
Uludag H, D'Augusta D, Golden J, Li J, Timony G, Riedel R, Wozney JM. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: A correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model Journal of Biomedical Materials Research. 50: 227-238. PMID 10679688 DOI: 10.1002/(Sici)1097-4636(200005)50:2<227::Aid-Jbm18>3.0.Co;2-2 |
0.405 |
|
| 2000 |
Uludag H, Wong M, Man J. Reactivity of temperature-sensitive, protein-conjugating polymers prepared by a photopolymerization process Journal of Applied Polymer Science. 75: 583-592. DOI: 10.1002/(Sici)1097-4628(20000124)75:4<583::Aid-App15>3.0.Co;2-L |
0.325 |
|
| 1999 |
Uludag H, Golden J, Palmer R, Wozney JM. Biotinated bone morphogenetic protein-2: In vivo and in vitro activity Biotechnology and Bioengineering. 65: 668-672. PMID 10550773 DOI: 10.1002/(Sici)1097-0290(19991220)65:6<668::Aid-Bit7>3.0.Co;2-8 |
0.499 |
|
| 1999 |
Winn SR, Uludag H, Hollinger JO. Carrier systems for bone morphogenetic proteins Clinical Orthopaedics and Related Research. PMID 10546639 DOI: 10.1097/00003086-199910001-00010 |
0.52 |
|
| 1999 |
Friess W, Uludag H, Foskett S, Biron R, Sargeant C. Characterization of absorbable collagen sponges as rhBMP-2 carriers International Journal of Pharmaceutics. 187: 91-99. PMID 10502616 DOI: 10.1016/S0378-5173(99)00174-X |
0.436 |
|
| 1999 |
Winn SR, Randolph G, Uludag H, Wong SC, Hair GA, Hollinger JO. Establishing an immortalized human osteoprecursor cell line: OPC1 Journal of Bone and Mineral Research. 14: 1721-1733. PMID 10491220 DOI: 10.1359/Jbmr.1999.14.10.1721 |
0.411 |
|
| 1999 |
Friess W, Uludag H, Foskett S, Biron R. Bone regeneration with recombinant human bone morphogenetic protein-2 (rhBMP-2) using absorbable collagen sponges (ACS): Influence of processing on ACS characteristics and formulation Pharmaceutical Development and Technology. 4: 387-396. PMID 10434284 DOI: 10.1081/Pdt-100101374 |
0.416 |
|
| 1999 |
Friess W, Uludag H, Foskett S, Biron R, Sargeant C. Characterization of absorbable collagen sponges as recombinant human bone morphogenetic protein-2 carriers International Journal of Pharmaceutics. 185: 51-60. PMID 10425365 DOI: 10.1016/S0378-5173(99)00128-3 |
0.461 |
|
| 1999 |
Uludag H, Friess W, Williams D, Porter T, Timony G, D'Augusta D, Blake C, Palmer R, Biron B, Wozney J. rhBMP-collagen sponges as osteoinductive devices: effects of in vitro sponge characteristics and protein pI on in vivo rhBMP pharmacokinetics. Annals of the New York Academy of Sciences. 875: 369-78. PMID 10415583 DOI: 10.1111/J.1749-6632.1999.Tb08519.X |
0.404 |
|
| 1999 |
Uludag H, D'Augusta D, Palmer R, Timony G, Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model Journal of Biomedical Materials Research. 46: 193-202. PMID 10379997 DOI: 10.1002/(Sici)1097-4636(199908)46:2<193::Aid-Jbm8>3.0.Co;2-1 |
0.399 |
|
| 1998 |
Winn SR, Uludag H, Hollinger JO. Sustained release emphasizing recombinant human bone morphogenetic protein-2 Advanced Drug Delivery Reviews. 31: 303-318. DOI: 10.1016/S0169-409X(97)00126-9 |
0.5 |
|
| 1998 |
Uludag H. Osteoinductive alternatives and bone substitutes Current Opinion in Orthopaedics. 9: 31-37. |
0.404 |
|
| Show low-probability matches. |